Inogen (INGN) Projected to Post Earnings on Thursday

Key Points

• Inogen is set to release its Q2 2025 earnings on August 7, with analysts predicting an earnings loss of ($0.25) per share and revenue of $90.40 million.
• Inogen reported a quarterly revenue of $82.28 million in its last earnings announcement, surpassing estimates, while also beating EPS forecasts by $0.27.
• Recent analyst ratings have varied, with Needham raising Inogen to a "moderate buy" with a $12.00 price target, while Stifel Nicolaus decreased their target to $7.00 and maintained a "hold" rating.

Inogen (NASDAQ:INGN - Get Free Report) is expected to be announcing its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $90.40 million for the quarter. Inogen has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Inogen (NASDAQ:INGN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.27. Inogen had a negative return on equity of 14.76% and a negative net margin of 8.08%. The business had revenue of $82.28 million for the quarter, compared to analysts' expectations of $79.57 million. On average, analysts expect Inogen to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Inogen Price Performance

Shares of NASDAQ:INGN traded down $0.10 during midday trading on Friday, hitting $6.21. The company had a trading volume of 444,994 shares, compared to its average volume of 169,161. Inogen has a twelve month low of $5.70 and a twelve month high of $13.33. The stock has a market cap of $166.99 million, a price-to-earnings ratio of -5.40 and a beta of 1.72. The business's 50-day simple moving average is $6.71 and its 200-day simple moving average is $7.72.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of INGN. Integrated Wealth Concepts LLC acquired a new position in shares of Inogen in the 1st quarter worth approximately $85,000. Jane Street Group LLC purchased a new stake in Inogen in the first quarter valued at approximately $463,000. Goldman Sachs Group Inc. lifted its stake in Inogen by 16.9% during the first quarter. Goldman Sachs Group Inc. now owns 284,180 shares of the medical technology company's stock worth $2,026,000 after purchasing an additional 41,002 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Inogen by 30.1% during the first quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company's stock worth $4,022,000 after buying an additional 130,381 shares during the period. Institutional investors and hedge funds own 89.94% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on INGN shares. Stifel Nicolaus cut their target price on Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Needham & Company LLC upgraded shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price objective for the company in a research report on Thursday, May 22nd. Finally, B. Riley started coverage on shares of Inogen in a report on Monday, June 16th. They issued a "buy" rating and a $14.00 target price on the stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.